Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2022 | The development of surgery for lung cancer with the evolution of neoadjuvant/adjuvant treatment

Paul Van Schil, MD, PhD, University Hospital Antwerp (UZA), Edegem, Belgium, discusses the evolution of surgery for lung cancer treatment with the wider introduction of adjuvant and neoadjuvant treatment. Although some clinicians suspect the use of surgery will decline, Prof. Schil believes this not to be the case, particularly for smaller lesions where the tumor can be analyzed for targetable mutations and does not need to be completely removed. This interview took place during the virtual European Lung Cancer Congress 2022.